Obtaining an upper estimate of the survival benefit associated with surgery for mesothelioma

European Journal of Cardio-thoracic Surgery

Volumn 38, Issue 3, 2010, Pages 241-244

  Utley, Martin ^a   Fiorentino, Francesca ^a   Treasure, Tom ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Asbestos; Mesothelioma; Multimodality therapy

Indexed keywords

ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; MULTIMODALITY CANCER THERAPY; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; THORACOTOMY;

COMBINED MODALITY THERAPY; HUMANS; MESOTHELIOMA; PLEURAL NEOPLASMS; PNEUMONECTOMY; SURVIVAL ANALYSIS; THORACOTOMY; TREATMENT OUTCOME;

EID: 77955922992     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2010.02.028     Document Type: Article

References (15)

1. Peto J., Decarli A., La Vecchia C., Levi F., Negri E. The European mesothelioma epidemic. Br J Cancer 1999, 79:666-672.
2. Hodgson J.T., McElvenny D.M., Darnton A.J., Price M.J., Peto J. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005, 92:587-593.
3. Okello C., Treasure T., Nicholson A.G., Peto J., Moller H. Certified causes of death in patients with mesothelioma in South East England. BMC Cancer 2009, 9:28.
4. Hasani A., Alvarez J.M., Wyatt J.M., Bydder S., Millward M., Byrne M., Musk A.W., Nowak A.K. Outcome for patients with malignant pleural mesothelioma referred for trimodality therapy in Western Australia. J Thorac Oncol 2009, 4:1010-1016.
5. Tsao A.S., Wistuba I., Roth J.A., Kindler H.L. Malignant Pleural Mesothelioma. J Clin Oncol 2009, 27:2081-2090.
6. Treasure T., Utley M. Ten traps for the unwary in surgical series: a case study in mesothelioma reports. J Thorac Cardiovasc Surg 2007, 133:1414-1418.
7. Flores R.M., Zakowski M., Venkatraman E., Krug L., Rosenzweig K., Dycoco J., Lee C., Yeoh C., Bains M., Rusch V. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol 2007, 2:957-965.
8. Treasure T., Utley M. Mesothelioma: benefit from surgical resection is questionable. J Thorac Oncol 2007, 2:885-886.
9. Cox D., Oakes D. Analysis of survival data 1984, Chapman and Hall, London, p. 145-146.
10. Swinscow T., Campbell M. Statistics at square one 2002, BMJ Books, p. 25-26. 10th ed.
11. Flores R.M., Pass H.I., Seshan V.E., Dycoco J., Zakowski M., Carbone M., Bains M.S., Rusch V.W. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008, 135:620-626.
12. Nakas A., Trousse D.S., Martin-Ucar A.E., Waller D.A. Open lung-sparing surgery for malignant pleural mesothelioma: the benefits of a radical approach within multimodality therapy. Eur J Cardiothorac Surg 2008, 34:886-891.
13. Sugarbaker D.J., Flores R.M., Jaklitsch M.T., Richards W.G., Strauss G.M., Corson J.M., DeCamp M.M., Swanson S.J., Bueno R., Lukanich J.M., Healey Baldini E., Mentzer S.J. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999, 117:54-63.
14. Tilleman T.R., Richards W.G., Zellos L., Johnson B.E., Jaklitsch M.T., Mueller J., Yeap B.Y., Mujoomdar A.A., Ducko C.T., Bueno R., Sugarbaker D.J. Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. J Thorac Cardiovasc Surg 2009, 138:405-411.
15. Treasure T., Waller D., Tan C., Entwisle J., O'Brien M., O'Byrne K., Thomas G., Snee M., Spicer J., Landau D., Lang-Lazdunski L., Bliss J., Peckitt C., Rogers S., Marriage E., Coombes G., Webster-Smith M., Peto J. The mesothelioma and radical surgery randomized controlled trial: the MARS feasibility study. J Thorac Oncol 2009, 4:1265-1268.